Author

Elisabetta Rovida

University of FlorenceORCID 0000-0002-5949-3239Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Atanasio PandiellaiD· 2 shared Azucena Esparı́s-OgandoiD· 2 shared Ignazia TusaiD· 2 shared Ylenia SfraganoiD· 2 shared Alessandro TubitaiD· 1 shared Alessio MenconiiD· 1 shared Antonio Fernández-Aramburo· 1 shared Barbara A. SteccaiD· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Atanasio PandiellaORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ERK5 inhibition triggers CDK6 proteasomal degradation and enhances palbociclib efficacy in cancer cells

Claudia Faundez Vidiella, Ylenia Sfragano, Ignazia Tusa, Barbara A. Stecca, Sergio Espinosa-Gil, José Miguel Lizcano, Elisabetta Rovida

This study shows that inhibiting ERK5 causes CDK6 degradation and enhances palbociclib's effectiveness in melanoma and endometrial cancer cells.

bioRxiv · Sep 18, 2026 · PreprintCancer Biology

R-Ras coordinates reciprocal activation of ERK5 and ERK1/2 under single pathway inhibition in melanoma

Ignazia Tusa, Cosimo Mazzei, Dimitri Papini, Alessio Menconi, Ylenia Sfragano, Alessandro Tubita, Giulia Montemurro, Julia Penitenti, Azucena Esparı́s-Ogando, Atanasio Pandiella, Elisabetta Rovida

This study shows that R-Ras coordinates reciprocal activation of ERK5 and ERK1/2 pathways in melanoma under MAPK inhibition, suggesting co-targeting R-Ras and MAPK signaling could improve therapy.

bioRxiv · Jul 20, 2026 · PreprintCancer Biology

VCAN is essential for ERK5-driven tumorigenesis in soft tissue sarcoma

Jaime Jiménez‐Suárez, Francisco J. Cimas, José Joaquín Paricio, Borja Belandia, Yosra Berrouayel, Elena Arconada‐Luque, Sofía Matilla-Almazán, Cesare Soffientini, Stefano Percio, Silvia Redondo-García, Natalia García-Flores, Cristina Garnés‐García, Pablo Fernández‐Aroca, Juan Jesus Martinez-Gomez, Antonio Fernández-Aramburo, , Ricardo Sánchez‐Prieto

This study identifies VCAN as a novel transcriptional target of ERK5 and shows its essential role in ERK5-driven tumorigenesis in soft tissue sarcoma.

International Journal of Biological Sciences · Feb 4, 2026Peer-reviewedCancer Biology